Johnson & Johnson stock holds above dividend level as 2026 guidance climbs
Published on 08/24/2026 at 16:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson (ISIN US4781601046) stock is trading in the low $270s as of August 23, 2026, with a market capitalization reported at $651.38 billion and a price-to-earnings ratio of 31.32 per recent market data. The shares carry a cash dividend of $1.34 per share scheduled for early September 2026, supporting a forward yield near 2 percent for income-focused investors. At the same time, the company has increased its full-year 2026 sales and earnings guidance, reinforcing expectations that annual revenue will pass the $100 billion mark for the first time in its history.
Guidance raised after Q2 2026
Recent coverage of Johnson & Johnson’s latest results indicates that the company ended fiscal Q2 2026 with $21 billion of cash and marketable securities, underscoring a strong balance sheet as it navigates litigation settlements and ongoing investment in its pharmaceutical and medtech pipelines. In that same context, management increased the midpoint of its reported sales guidance for 2026 to $101.1 billion, signaling that the business now aims to cross the $100 billion annual revenue threshold for the first time over the current year. The midpoint of adjusted earnings per share guidance for 2026 was lifted by $0.13 to $11.68, a change that points to higher profitability expectations compared with prior internal forecasts.
The guidance revision came as the innovative medicines segment continued to grow. One recent analysis notes that innovative medicine sales rose 7.8 percent year over year to $16.38 billion in the latest reported quarter, or 6.8 percent operationally, even though lower sales of Stelara reduced the operational growth rate by 760 basis points. That segment performance provides context for the updated full-year outlook, because it indicates that Johnson & Johnson’s core drug portfolio is still expanding despite individual products moving closer to loss of exclusivity and facing competition from biosimilars.
Dividend and valuation context
For investors focused on cash returns, Johnson & Johnson’s upcoming dividend is a central part of the stock’s appeal. A recent dividend overview shows that the company declared a cash dividend of $1.340 per share with an ex-dividend date on August 25, 2026 and a pay date on September 8, 2026, maintaining its long record of regular quarterly distributions. At the closing price of $267.37 on August 20, 2026, that dividend level corresponded to an indicated annual payout of $5.36 per share and a stated dividend yield of 2.0 percent, combining income with exposure to a diversified healthcare business. The same data set records an intraday quote of $267.87 on August 20, 2026, reflecting a modest 0.19 percent gain during that session that fits with the relatively defensive behavior often seen in large-cap healthcare names.
Market data from another portal gives a slightly different perspective on the share price and capitalization. One snapshot shows Johnson & Johnson at a stock price of $271.00 with a market capitalization of $651.38 billion and a price-to-earnings ratio of 31.32 as of August 23, 2026; during that session the shares traded in an intraday range between $267.00 and $272.66, leaving the last price 1.5 percent above the day’s low and 0.6 percent below the high. That price level sits modestly above a consensus target price of $268.22 reported in a recent institutional-ownership summary, implying that the shares are trading slightly ahead of average analyst expectations while still close to where Wall Street models see fair value.
Analyst view and risk backdrop
In addition to the dividend and valuation metrics, recent commentary highlights how the market is interpreting Johnson & Johnson’s litigation and pipeline backdrop. One article focusing on the company’s talc settlement noted that management had reached a $5.5 billion agreement related to talc claims and emphasized that this came in the context of ending Q2 2026 with $21 billion in cash and marketable securities. That cash position is significant because it provides flexibility to absorb settlement costs while still funding research, acquisitions, and shareholder returns, reinforcing the investment case for the stock as a relatively stable healthcare holding.
Broader market commentary also indicates that healthcare stocks have been contributing positively to recent equity performance. In an overview of the latest trading session, the same coverage observed that Johnson & Johnson shares gained 1.1 percent, alongside a 0.9 percent rise for another large pharmaceutical peer, signaling that defensive healthcare names have helped offset weakness elsewhere in the market. This performance pattern aligns with Johnson & Johnson’s role as a diversified healthcare conglomerate whose earnings and dividend profile can offer ballast when more cyclical sectors come under pressure.
Key products and business mix
Johnson & Johnson’s investment case still hinges on its mix of pharmaceuticals, medical devices, and consumer health products, with innovative medicine growth standing out in the latest quarter. The reported 7.8 percent year-over-year increase in innovative medicine sales to $16.38 billion in Q2 2026 suggests that new therapies and expanded indications are successfully offsetting pressure from maturing products. The segment’s 6.8 percent operational growth, even after the drag from Stelara, underscores how a broad portfolio can smooth out product-specific volatility. For long-term shareholders, this combination of growth in key treatments and steady cash generation underpins the ability to sustain dividends, fund litigation settlements, and invest in future launches.
Johnson & Johnson stock and current market level
Johnson & Johnson stock currently trades around the upper-$260s to low-$270s region based on recent quotes, with a closing price of $267.37 on August 20, 2026 at 4:00 p.m. ET and an indicated intraday level of $271.00 on August 23, 2026. Taken together, those figures show the shares holding slightly above the latest consensus target of $268.22 while offering a dividend yield of 2.0 percent from an annualized $5.36 per-share payout. For investors, the combination of raised 2026 guidance to a midpoint of $101.1 billion in sales and $11.68 in adjusted EPS, a robust $21 billion cash balance at the end of Q2 2026, and a visible dividend stream positions Johnson & Johnson as a large-cap healthcare stock where current returns are supported by both operating momentum and financial strength.
Read more
Further details on Johnson & Johnson’s dividend schedule and recent market data can be found in the latest dividend overview and stock quote pages, which summarize ex-dividend dates, pay dates, and recent closing prices for the shares.
Fact box
Company: Johnson & Johnson
ISIN: US4781601046
Ticker: JNJ
Exchange: NYSE
Price (as of August 23, 2026): $271.00 USD
Market cap: $651.38 billion (as of August 23, 2026)
Sector / Industry: Healthcare / Pharmaceuticals, Medtech
Index membership: Dow Jones Industrial Average, S&P 500
